Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06332131 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jul 2026 → Nov 2026
See other at-risk trials from Abramson Cancer Center at Penn Medicine

Record History

  1. Trial status changed: Enrolling by Invitation → Active, Not Recruiting Primary and study completion pushed from Jul 2026 to Nov 2026 · Eligibility criteria expanded, about 7 words · Secondary endpoints: details revised at 2 of 4 entries Show 3 more changesShow less
    • Primary and study completion pushed from Jul 2026 to Nov 2026
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 2 of 4 entries
  2. Primary and study completion dates: May 2026 to Jul 2026v10
  3. Trial status: Not Yet Recruiting to Enrolling by Invitation Primary and study completion dates: May 2027 to May 2026 · Start date changed from estimate of Dec 2024 to Jan 15, 2025 · Secondary endpoints: details revised at 4 of 4 entriesv9 Show 3 more changesShow less
    • Primary and study completion dates: May 2027 to May 2026
    • Start date changed from estimate of Dec 2024 to Jan 15, 2025
    • Secondary endpoints: details revised at 4 of 4 entries
  4. Primary and study completion dates: Apr 2027 to May 2027 Start date: Nov 2024 to Dec 2024v8 Show 1 more changeShow less
    • Start date: Nov 2024 to Dec 2024
  5. Eligibility criteria expanded, about 13 wordsv7 See this version in full on ClinicalTrials.gov ↗
Show 5 earlier versionsHide 5 earlier versions
  1. Start date: Jul 2024 to Nov 2024v6
  2. Start date: Jun 2024 to Jul 2024v5
  3. Start date: May 2024 to Jun 2024v4
  4. Start date: Apr 2024 to May 2024v3
  5. Eligibility criteria shortened, about 75 words Secondary endpoints: details revised at 1 of 4 entriesv2 Show 1 more changeShow less
    • Secondary endpoints: details revised at 1 of 4 entries

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an observational study that includes patients with breast cancer or non-small cell lung cancer who will be treated with immune checkpoint inhibitor (ICI) therapy. The investigators will use echocardiograms, blood draws, and PET stress tests to understand how ICI therapy affects the heart and circulatory system.
Trial Details
NCT Number NCT06332131
Lead Sponsor Abramson Cancer Center at Penn Medicine
Conditions Coronary Microvascular Dysfunction, Cardiotoxicity, Breast Cancer, Lung Cancer (NSCLC)
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov